Antibodies to watch in 2024
S Crescioli, H Kaplon, A Chenoweth, L Wang… - MAbs, 2024 - Taylor & Francis
ABSTRACT The 'Antibodies to Watch'article series provides an annual summary of
commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical …
commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical …
Rademikibart (CBP‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα: Two phase I randomized trials, in healthy individuals and patients with …
J Wang, J White, KJ Sansone… - Clinical and …, 2023 - Wiley Online Library
Abstract IL‐4 and IL‐13 signaling via IL‐4Rα plays key roles in the pathogenesis of atopic
dermatitis (AD) and asthma. Rademikibart (formerly CBP‐201), a next‐generation human …
dermatitis (AD) and asthma. Rademikibart (formerly CBP‐201), a next‐generation human …
Role of differentiated embryo-chondrocyte expressed gene 2 in immunity
Y Li, Y Ma, Y Liu, N Tang, W Zhang, J Huo… - Frontiers in …, 2024 - frontiersin.org
Differentiated embryo-chondrocyte expressed gene 2 (DEC2) is a member of the basic helix-
loop-helix (bHLH) subfamily of transcription factors. DEC2 is implicated in tumor …
loop-helix (bHLH) subfamily of transcription factors. DEC2 is implicated in tumor …
Monoclonal antibodies for moderate-to-severe atopic dermatitis: a look at phase III and beyond
E David, K Hawkins, N Shokrian… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction The understanding of atopic dermatitis (AD) pathogenesis has rapidly
expanded in recent years, catalyzing the development of new targeted monoclonal antibody …
expanded in recent years, catalyzing the development of new targeted monoclonal antibody …
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial …
JI Silverberg, B Strober, B Feinstein, J Xu… - Journal of Allergy and …, 2024 - Elsevier
Background Rademikibart (CBP-201) is a next-generation IL-4 receptor alpha–targeting
antibody. Objective We sought to evaluate rademikibart in adults with moderate to severe …
antibody. Objective We sought to evaluate rademikibart in adults with moderate to severe …
Emerging drugs for the treatment of atopic dermatitis: a focus on phase 2 and phase 3 trials
O Obed, AC Chong, M Su, PY Ong - Expert Opinion on Emerging …, 2024 - Taylor & Francis
Introduction Atopic dermatitis (AD) is an inflammatory skin condition that affects millions of
pediatric and adult patients with well-studied impact on morbidity and quality of life …
pediatric and adult patients with well-studied impact on morbidity and quality of life …
Pathogenesis-based application of biologics for chronic rhinosinusitis: Current and future perspectives
M Okano, K Kanai, A Oka - Auris Nasus Larynx, 2023 - Elsevier
Chronic rhinosinusitis (CRS) is heterogeneous and contains diverse pathogenesis including
type 1, type 2, and/or type 3 inflammation. For severe type 2 CRS especially CRS with nasal …
type 1, type 2, and/or type 3 inflammation. For severe type 2 CRS especially CRS with nasal …
IL‐4/IL‐13 pathway in nasal type 2 inflammation: The central role and targeted therapy
Z Zhu, C Zhao, M Wang - Eye & ENT Research, 2024 - Wiley Online Library
Type 2 dominant inflammation in nasal mucosa is the key underlying pathophysiological
mechanism of allergic rhinitis (AR) and most presentations of chronic rhinosinusitis with …
mechanism of allergic rhinitis (AR) and most presentations of chronic rhinosinusitis with …
[PDF][PDF] Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Ra, in adults with moderate to severe atopic dermatitis: A phase 2 …
JI Silverberg, B Strober, B Feinstein, J Xu - 2023 - feinsteindermatology.com
Background: Rademikibart (CBP-201) is a next-generation IL-4 receptor alpha–targeting
antibody. Objective: We sought to evaluate rademikibart in adults with moderate to severe …
antibody. Objective: We sought to evaluate rademikibart in adults with moderate to severe …